Three separate stock-price plunges over nine months wiped out millions for Zoetis investors. The first came August 5, 2025, after the company reported weak demand in its Companion Animal portfolio. Then November 4, 2025, when Zoetis cut its full-year sales outlook and disclosed continued weakness in Librela, its canine pain treatment, plus rising competitive pressure in dermatology and parasiticides.
The third hit May 7, 2026, after first-quarter results showed slowing overall revenue growth and declining Companion Animal sales. Each disclosure landed like a hammer.
Investors who bought Zoetis securities between January 14, 2025, and May 6, 2026, are now staring at losses. The law firm Glancy Prongay Wolke & Rotter LLP is rounding them up. The lead plaintiff motion deadline is approaching in the class action lawsuit filed under federal securities laws.
Zoetis is the world’s largest animal health company. Its core business is supposed to be steady — pets get sick, owners pay.
But Librela, once a growth driver, is now a drag. The company acknowledged continued weakness in sales of the canine osteoarthritis treatment. At the same time, competitors are eating into Zoetis’ dermatology and parasiticide markets.
The company described the situation as “increased competitive pressure.” That is corporate-speak for losing market share. The financial damage is not abstract. On August 5, 2025, after the second-quarter miss, the stock fell sharply.
On November 4, 2025, it fell again. Then on May 7, 2026, the first-quarter numbers triggered another decline.
Three strikes. Investors who held through all three saw the value of their holdings erode repeatedly. The class action aims to recover some of that money.
But securities lawsuits are long, expensive, and uncertain. Lead plaintiffs get appointed.
Discovery happens. Motions fly. Years pass.
What to watch next. The lead plaintiff deadline will determine who steers the case. Law firms compete for that role — it means control and fees.
Glancy Prongay Wolke & Rotter is making its pitch now, urging investors to contact them. Other firms will likely do the same.
The court will pick the investor or group with the largest financial interest who also meets the adequacy and typicality requirements. The underlying business problems remain. Zoetis has not fixed the Librela weakness.
It has not reversed the competitive pressure in dermatology and parasiticides. The company’s next quarterly report will show whether those trends are stabilizing or worsening.
If the results continue to disappoint, more stock drops could follow. That would expand the class period and deepen the losses. For now, investors are left watching two clocks.
One is the lead plaintiff deadline, ticking toward a date only the court knows for sure. The other is Zoetis’ next earnings release, which will tell them whether the company has any answers. Neither clock is on their side.
